Results 51 to 60 of about 6,610 (196)

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Improving Palivizumab Compliance Through a Pharmacist-Managed RSV Prevention Clinic

, 2017
OBJECTIVESPalivizumab is a monoclonal antibody approved for the prevention of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk pediatric patients.
Jennifer W. Chow, John Harrington, Carolyn S. Moneymaker, Anthony M. Christensen, Michael F. Chicella, James E. Dice   +5 more
core   +1 more source

Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden

, 2004
AIM: Palivizumab (Synagis) was registered in Sweden in 1999 for prophylaxis against respiratory syncytial virus (RSV) in premature infants. The high costs and the limited knowledge of the efficacy of this substance have led to debate about how and when ...
Eriksson, M., Ewald, Uwe,, Linde, A., Lindroth, M., Naver, Lars, Schollin, J.   +5 more
core   +2 more sources

Palivizumab: Four Seasons in Russia

Annals of the Russian academy of medical sciences, 2014
In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically ...
Baranov A.A., Ivanov D.O., Alyamovskaya G.A., Amirova V.R., Antonyuk I.V., Asmolova G.A., Belyaeva I.A., Bokeriya E.L., Bryukhanova O.A., Vinogradova I.V., Vlasova E.V., Galustyan A.N., Gafarova G.V., Gorev V.V., Davydova I.V., Degtyarev D.N., Degtyareva E.A., Dolgikh V.V., Donin I.M., Zakharova N.I., Zernova L.Yu., Zimina E.P., Zuev V.V., Keshishyan E.S., Kovalev I.A., Koltunov I.E., Korsunskii A.A., Krivoshchekov E.V., Krsheminskaya I.V., Kuznetsova S.N., Lyubimenko V.A., Namazova-Baranova L.S., Nesterenko E.V., Nikolaev S.V., Ovsyannikov D.Yu., Pavlova T.I., Potapova M.V., Rychkova L.V., Safarov A.A., Safina A.I., Skachkova M.A., Soldatova I.G., Turti T.V., Filatova N.A., Shakirova R.M., Yanulevich O.S.   +45 more
openaire   +5 more sources

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation

Health Technology Assessment, 2008
Objectives: To systematically review the effectiveness and cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) in children and examine prognostic factors to determine whether subgroups can be identified with ...
D Wang, C Cummins, S Bayliss, J Sandercock, A Burls   +4 more
doaj   +1 more source

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration

Human Vaccines & Immunotherapeutics, 2023
Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommended ...
Elizabeth R. Packnett, Isabelle H. Winer, Abiola Oladapo, Matthew Wojdyla   +3 more
doaj   +1 more source

The Medicaid Cost of Palivizumab [PDF]

Journal of the Pediatric Infectious Diseases Society, 2014
To the editor—Borse et al. [1] describe an economic analysis of respiratory syncytial virus (RSV) prophylaxis for infants in Alaska's Yukon-Kuskokwim Delta. The authors should be congratulated for evaluating this important question with a robust analysis. As these infants are almost entirely insured by Medicaid, we wish to clarify the net Medicaid cost
Ambrose, Christopher S., McLaurin, Kimmie K.   +1 more
openaire   +1 more source

Multiomics Identification and Validation of an Integrin–Extracellular Matrix Network Driving Respiratory Syncytial Virus‐Induced Lung Injury and Repair

MedComm, Volume 7, Issue 7, July 2026.
This graphical abstract depicts the dynamic progression from acute lung inflammation to fibrotic repair following RSV infection. Multiomics analysis uncovers a central regulatory network coordinating key pathways including coagulation, extracellular matrix deposition, integrin signaling, and cytoskeletal reorganization.
Lili Zhou, Hua Guo, Xiaofeng Yu, Yu Ran, Ruiqi Liu, Jiali Zhu, Ran Li, Jie Xu, Leshi Chen, Yongliang Zhu, Long Zhang, Zhenjiang Bai, Fangfang Zhou   +12 more
wiley   +1 more source

Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009. [PDF]

, 2010
This study was performed to evaluate the utilization and outcomes of palivizumab in high risk children born prematurely with chronic lung disease (CLD).
Chang, SG, Park, MS, Yu, JE
core   +1 more source

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro

The Turkish Journal of Pediatrics
Background. Respiratory syncytial virus (RSV) is one of the most common pathogens causing severe lower respiratory tract disease in infancy and childhood.
Envera Lekic, Ljubinka Dragas, Drasko Nikcevic, Jasmina Lekic, Ana Dedic, Ljiljana Sulovic   +5 more
doaj   +1 more source